Pharma

Pharmalot

Pharmalittle: Insulin dominates Democrats’ health agenda in Iowa; FDA studies Instagram influencers

By Ed Silverman

Pharmalot

Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market

By Ed Silverman

Pharmalot

Big drug purchasers predict price hikes driven by expensive new therapies

By Ed Silverman

Pharmalot

McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments

By Ed Silverman

Pharmalot

Roche is fined by Romania for thwarting competition to its cancer medicines

By Ed Silverman

Pharmalot

Pharmalittle: Coronavirus spread may hurt pharma’s supply chain; Illinois limits out-of-pocket insulin costs

By Ed Silverman

Pharmalot

‘The time to worry is now’: The coronavirus in China could threaten pharma’s ingredient sourcing

By Ed Silverman

Pharmalot

Another patient charity settles charges it helped drug makers pay Medicare kickbacks

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharma

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Drug makers spent $120 million lobbying Congress in 2019; more investors are bullish on Biogen’s Alzheimer drug

By Ed Silverman

Business

Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence

By Jonathan Saltzman — Boston Globe

Pharmalot

Many patient groups have deep ties to pharma but fail to disclose backing

By Ed Silverman

Pharmalot

Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug

By Ed Silverman

Pharmalot

Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics

By Ed Silverman

Pharmalot

European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case

By Ed Silverman

Pharmalot

European court upholds controversial EMA transparency rules for clinical trial data

By Ed Silverman

Pharmalot

Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production

By Ed Silverman

Pharmalot

As prescribing for ADHD stimulants rose, so did industry payments to doctors

By Ed Silverman

Pharmalot

Pharma is making some effort to fight superbugs, but progress is ‘patchy’

By Ed Silverman

Pharmalot

Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug

By Elizabeth Cooney

Pharmalot

Lilly exec says ‘there are no villains’ in the high-priced insulin market

By Ed Silverman

Pharmalot

Pharmalittle: Tension in the Verily-Dexcom tango; not so fast on the Pfizer-GSK spinoff

By Elizabeth Cooney

Pharmalittle: Novartis says coronavirus not disrupting supply chain, for now; FDA releases new gene therapy policies

Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

The FDA wants to know how Instagram influencers sway patient views on medicines

Drug makers face more securities-fraud lawsuits, and so do cannabis companies

Pharmalittle: Insulin dominates Democrats’ health agenda in Iowa; FDA studies Instagram influencers

Martin Shkreli is sued by the FTC and NY attorney general for illegally cornering a market

Big drug purchasers predict price hikes driven by expensive new therapies

McKesson reaches $175 million deal with shareholders over lax oversight of opioid shipments

Roche is fined by Romania for thwarting competition to its cancer medicines

Pharmalittle: Coronavirus spread may hurt pharma’s supply chain; Illinois limits out-of-pocket insulin costs

‘The time to worry is now’: The coronavirus in China could threaten pharma’s ingredient sourcing

Another patient charity settles charges it helped drug makers pay Medicare kickbacks

Up and down the ladder: The latest comings and goings

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

Pharmalittle: Drug makers spent $120 million lobbying Congress in 2019; more investors are bullish on Biogen’s Alzheimer drug

Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence

Many patient groups have deep ties to pharma but fail to disclose backing

Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug

Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics

European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case

European court upholds controversial EMA transparency rules for clinical trial data

Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production

As prescribing for ADHD stimulants rose, so did industry payments to doctors

Pharma is making some effort to fight superbugs, but progress is ‘patchy’

Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported

Up and down the ladder: The latest comings and goings

Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug

Lilly exec says ‘there are no villains’ in the high-priced insulin market

Pharmalittle: Tension in the Verily-Dexcom tango; not so fast on the Pfizer-GSK spinoff